Skip to main content

Eton Pharmaceuticals, Inc.

corporate_fare Company Profile

Eton Pharmaceuticals, Inc.

ETON·NASDAQ·Life Sciences·CIK 0001710340

Eton is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently has eight commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, KHINDIVI TM , GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. Eton also has five additional product candidates in late-stage development: ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. INCRELEX® is a biologic product approved by the FDA in August 2005 for treating children with severe primary insulin-like growth factor 1 deficiency (SPIGFD). It is approved in 40 territories, including the United States and the European Union. Eton acquired and launched INCRELEX® in December 2024. ALKINDI SPRINKLE® was approved by the FDA in September 2020 as a replacement therapy for Adrenocortical Insufficiency ("AI") in children under 17 years of age. It is the first and only FDA-approved granule hydrocortisone formulation designed for accurate dosing in newborns and children with AI. Eton acquired U.S. marketing rights in March 2020 and launched ALKINDI SPRINKLE® in December 2020. The product is protected by three issued patents extending to 2032, 2033, and 2034. KHINDIVI TM was approved by the FDA in May 2025 as a replacement therapy for adrenocortical insufficiency in pediatric patients five years of age and older. It is the only FDA-approved oral solution formulation of hydrocortisone, available in a 1mg/ml strength. KHINDIVI is a ready-to-use oral liquid solution that does not require refrigeration, mixing, or shaking.

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 35 items for ETON at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for ETON spans 10-Q, 8-K, 4, 144.

Recent high-impact activity:

  • Eton Pharma Jumps 20% Premarket as Q3 Revenue Triples and Full-Year Guidance Raised to $175M+
  • Eton 10-Q: Q3 Sales $57.9M, Nine-Month Operating Cash Flow $49.9M, Cash Builds to $55.6M
  • Eton Q3 Sales $57.9M, Up 158%; 2026 Revenue Guidance Raised to >$175M
  • Eton Posts $1.06 Q3 EPS, Extending Blowout Earnings Streak
  • Eton's ET-700 Pilot: Better Tolerability, Weaker Copper Blocking Than GALZIN

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$79.95M
Net Income
-$4.6M
Op. Cash Flow
$10.52M
Free Cash Flow
$10.19M
Gross Profit
$42.74M
Operating Income
-$844K
Cash & Equivalents
$25.94M
Total Debt
$30.56M
Debt / Equity
1.17×
Net Margin
-5.8%
Shares Outstanding
27.05M sh
Source: 10-K · filed 2026-03-19 · accession 0001437749-26-009059

Short Interest & Short Volume

5.43 days to cover

FINRA reported short interest of 1,986,167 shares in ETON as of the October 30, 2026 settlement, a 2.2% increase from the prior period — about 5.4 days to cover at its recent average daily volume. On November 20, 2026, 47.8% of ETON volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,986,167 shares as of October 30, 2026
Change vs prior period▲ 2.2%
Days to cover5.43 at avg daily volume of 365,610
Daily short volume (FINRA facilities)47.8% of 201,643 shares on November 20, 2026
5-day average short volume53.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with E →
$60.85
52-week range · as of 2026-11-05 $14.27 – $66.37
Market cap
$1.76B
Volume
562.7K (1.0× avg)
3-mo avg 563.9K
Live data · 2026-11-22 09:21 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ETON - Latest Insights

ETON
Nov 06, 2026, 9:04 AM EST
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $58.86
Real-time Price: $60.85 info
Change: +$1.99 (+3%) info
Market Cap: $1.755B info
ETON
Nov 05, 2026, 4:32 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $57.90
Real-time Price: $60.85 info
Change: +$2.95 (+5%) info
Market Cap: $1.755B info
ETON
Nov 05, 2026, 4:13 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $56.06
Real-time Price: $60.85 info
Change: +$4.79 (+9%) info
Market Cap: $1.755B info
ETON
Nov 05, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $47.15
Real-time Price: $60.85 info
Change: +$13.70 (+29%) info
Market Cap: $1.755B info
ETON
Nov 05, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $47.15
Real-time Price: $60.85 info
Change: +$13.70 (+29%) info
Market Cap: $1.755B info
ETON
Nov 05, 2026, 4:01 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $58.85
Real-time Price: $60.85 info
Change: +$2.00 (+3%) info
Market Cap: $1.755B info
ETON
Oct 14, 2026, 6:50 AM EDT
Source: GlobeNewswire
Importance Score:
8
Updated Oct 14, 7:17 AM ET — Eton paid Aquestive a $10 million upfront fee, with up to $47.5 million in regulatory and commercial milestones and mid-teens royalties on…
Price at Filing: $55.55
Real-time Price: $60.85 info
Change: +$5.30 (+10%) info
Market Cap: $1.755B info
ETON
Sep 28, 2026, 6:50 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $57.68
Real-time Price: $60.85 info
Change: +$3.17 (+5%) info
Market Cap: $1.755B info
ETON
Aug 20, 2026, 6:26 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $60.23
Real-time Price: $60.85 info
Change: +$0.620 (+1%) info
Market Cap: $1.755B info
ETON
Aug 13, 2026, 4:19 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $51.00
Real-time Price: $60.85 info
Change: +$9.85 (+19%) info
Market Cap: $1.755B info
ETON
Aug 13, 2026, 4:16 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $51.30
Real-time Price: $60.85 info
Change: +$9.55 (+19%) info
Market Cap: $1.755B info
ETON
Aug 13, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $48.07
Real-time Price: $60.85 info
Change: +$12.78 (+27%) info
Market Cap: $1.755B info
ETON
Aug 05, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $46.00
Real-time Price: $60.85 info
Change: +$14.85 (+32%) info
Market Cap: $1.755B info
ETON
Aug 05, 2026, 6:50 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $46.00
Real-time Price: $60.85 info
Change: +$14.85 (+32%) info
Market Cap: $1.755B info
ETON
Jul 29, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $47.73
Real-time Price: $60.85 info
Change: +$13.12 (+27%) info
Market Cap: $1.755B info
ETON
Jul 07, 2026, 6:29 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $37.74
Real-time Price: $60.85 info
Change: +$23.11 (+61%) info
Market Cap: $1.755B info
ETON
Jun 26, 2026, 4:14 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $35.70
Real-time Price: $60.85 info
Change: +$25.15 (+70%) info
Market Cap: $1.755B info
ETON
Jun 17, 2026, 5:08 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $32.76
Real-time Price: $60.85 info
Change: +$28.09 (+86%) info
Market Cap: $1.755B info
ETON
May 29, 2026, 4:16 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $30.45
Real-time Price: $60.85 info
Change: +$30.40 (+100%) info
Market Cap: $1.755B info
ETON
May 28, 2026, 3:12 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $31.84
Real-time Price: $60.85 info
Change: +$29.01 (+91%) info
Market Cap: $1.755B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets